Azilsartan as “Add-On” Treatment with Methotrexate Improves the Disease Activity of Rheumatoid Arthritis
المؤلفون المشاركون
Hussain, Saad Abdulrahman
Mahmood, Naza Mohammed Ali
Khan, Hawar Ali Ehsan Kaka
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-05-15
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Objective.
The present study aimed to evaluate the efficacy and safety of azilsartan (Azil) as “add-on” treatment with methotrexate (MTX) in patients with active rheumatoid arthritis (RA).
Methods.
This single center, randomized, placebo-controlled, double-blind, pilot study included 64 patients with active RA.
Patients received either placebo or Azil in addition to their currently used MTX doses for 90 days.
The primary outcomes were DAS-28, SDAI, HAQ-DI, CDAI, EGA, and swollen and tender joints count.
The secondary outcomes were the changes in the pain visual analogue scale (VAS-100), serum levels of TNF-α, IL-1β, IL-6, and anti-CCP, the lipid profile, and the markers of kidney and liver functions in the two groups at baseline and after 90 days.
Results.
After 90 days, most clinical scores were significantly better in the Azil-treated group than in the placebo group.
All inflammatory biomarkers were significantly improved after treatment with MTX + Azil compared to baseline and placebo group.
No safety concerns were reported during the study period.
Conclusions.
Azilsartan improved the effects of methotrexate on the clinical scores and certain inflammatory biomarkers of patients with active RA.
Trial Registration.
The protocol was registered under the number 507/SA/1024 at the local clinical studies database, College of Medicine, Sulaimani University.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Mahmood, Naza Mohammed Ali& Hussain, Saad Abdulrahman& Khan, Hawar Ali Ehsan Kaka. 2018. Azilsartan as “Add-On” Treatment with Methotrexate Improves the Disease Activity of Rheumatoid Arthritis. BioMed Research International،Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1128300
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Mahmood, Naza Mohammed Ali…[et al.]. Azilsartan as “Add-On” Treatment with Methotrexate Improves the Disease Activity of Rheumatoid Arthritis. BioMed Research International No. 2018 (2018), pp.1-9.
https://search.emarefa.net/detail/BIM-1128300
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Mahmood, Naza Mohammed Ali& Hussain, Saad Abdulrahman& Khan, Hawar Ali Ehsan Kaka. Azilsartan as “Add-On” Treatment with Methotrexate Improves the Disease Activity of Rheumatoid Arthritis. BioMed Research International. 2018. Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1128300
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1128300
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر